Mutated Low-Grade Glioma

Trending

View All

Pharma News and Updates for AbbVie, Arrowhead Pharma, Novartis, FORE Biotherapeutics, Ellipses Pharma, Karuna Therapeutics

Mar 21, 2023

AbbVie Announces Results of Study Evaluating SKYRIZI; FDA Fast Track Designation to Arrowhead’s ARO-APOC3; FDA Approves Dabrafenib Plus Trametinib for BRAF V600E–Mutated Low-Grade Glioma; FDA Grants ODD to Novel BRAF Inhibitor for Brain/CNS Malignancies; EP0042 Wins FDA Orphan Drug Status; Karuna Therapeutics Announces Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia

AbbVie Announces Positive Results of Study Evaluating SKYRIZI in Plaque Psoriasis Patients AbbVie announced new 52-week data from an open-label, a single-arm study demonstrating improved plaque psoriasis signs and symptoms in a difficult-to-treat patient population who received SKYRIZI® (risankizumab), an IL-23 ...

Find More

Editor's Pick

Wainua – The Only Approved Medicine for hATTR-PN Treatment

lyfgenia-or-casgevy-for-sickle-cell-disease-treatment

Lyfgenia or Casgevy: Who Will Lead the Sickle Cell Disease Treatment Space?

Another Feather in the Cap for Xtandi and Keytruda — The Two Main Cancer Drugs

vabysmo-for-retinal-vein-occlusion-treatment

Roche’s Vabysmo Third US Approval Spiced Up the Battle With Regeneron and Bayer’s Eylea

AAV Gene Therapies for Hemophilia B Treatment: The Road to a Cure

Newsletter/Whitepaper

ASCO Conference 2023

The American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.

Catch the Glimpse here

By DelveInsight

Mutated Low-Grade Glioma

Search by Categories

Our expertise in the industry

View All

Editor's Pick

Newsletter/Whitepaper

ASCO Conference 2023